The impact of stigma on cognitive performance; risk factor dissonance among young black MSM; pregnancy and the HIV care continuum; new data on pediatric raltegravir use.
Despite their increased risk, only one-third of adolescents and young adults with known opioid use disorder were screened for hepatitis C, according to a study released at the IDWeek conference in San Francisco.
Efavirenz (Sustiva, Stocrin) use was associated with a 60% increased risk of neurological conditions in children, according to data presented at IDWeek 2018 in San Francisco.
The first global comparison of adolescents who acquired HIV as newborns highlights the challenges around treatment for children in developing countries.
The risk of transmitting HIV through the breastmilk of virally suppressed women in high-income countries is not known.
This recently updated fact sheet from the U.S. Centers for Disease Control and Prevention provides a quick rundown of the latest HIV infection numbers and prevention challenges impacting new moms and moms-to-be.
HIV incidence fell about 9% overall in a five-year span, the CDC found, but it rose in some groups, including people 25 to 29 years old, Asians, and American Indians.
Optimal doses of long-acting injectable antiretrovirals cabotegravir and rilpivirine were predicted for different weight bands in children and adolescents.
No HIV-exposed infants who were negative at birth, whose mothers started ART before delivery, had suppressed viral loads, and exclusively breastfed, were HIV positive after breastfeeding, in a rural African cohort.
Chewable raltegravir tablets can be crushed and stirred until dispersed in water, apple juice or breast milk and given to younger children according to WHO weight bands.